# Weekly Medical Cannabis & Science Literature Radar: September 13, 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/weekly-medical-cannabis-research-radar-2026-09-13/ > **Published:** 2026-09-13T11:25:31-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T12:42:45-04:00 > **Clinical Summary:** medical cannabis research radar: Weekly medical cannabis & science literature radar: analyzing 20 newly published PubMed papers, preprints, and clinical tria... --- CED Clinical Relevance #85 Weekly Literature Radar Continuous evidence tracking across 20 verified biomedical and regulatory sources. Clinical Insight | CED Clinic This Weekly Literature Radar delivers practical physician analysis of 20 newly published scientific studies, open-access preprints, and clinical trial registrations. By tracking multi-repository biomedical data across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides healthcare providers and patients with transparent, evidence-grounded analysis. Staying informed about emerging cannabinoid dosing data, drug interactions, and regulatory milestones ensures that clinical counseling remains grounded in verified facts above all, prioritizing patient safety and long-term health outcomes across every single clinical encounter. Research RadarCannabis ScienceTrial ProtocolsSafety SignalsLiterature Index AudiencePatients, clinicians, healthcare professionals, researchers, and policy analysts. Primary TopicWeekly medical cannabis and science research index (September 2026). Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42732434/) Table of Contents - [Weekly Medical Cannabis & Science Literature Radar: September 13, 2026](#Weekly_Medical_Cannabis_Science_Literature_Radar_September_13_2026)[How to Interpret the Weekly Research Radar](#How_to_Interpret_the_Weekly_Research_Radar)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [Weekly Literature Insights & Clinical Overview (September 2026)](#Weekly_Literature_Insights_Clinical_Overview_September_2026)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Weekly Medical Cannabis & Science Literature Radar: September 13, 2026 A comprehensive weekly literature index analyzing 20 newly published medical cannabis, cannabinoid, and GLP-1 research studies, clinical trial protocols, and regulatory updates. What This Study Teaches Us This literature cohort indexes 14 primary clinical and pharmacological updates, led by findings from PubMed investigating Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesi. The evaluated studies encompass randomized trials, systematic reviews, and longitudinal observational cohorts documenting quantitative symptom reductions, receptor mechanisms, and adverse effect profiles. Together, these publications clarify the distinction between subjective patient-reported relief and objective physiological endpoints across diverse patient populations. Why This Matters Evaluating multi-repository clinical trial data and peer-reviewed papers ensures patient counseling and clinical practice remain aligned with verified scientific findings. Understanding emerging pharmacokinetic data, drug-drug interaction risks, and cannabinoid ratios helps physicians tailor personalized care plans while minimizing unwanted side effects. Transparent literature monitoring provides an objective safeguard against commercial marketing claims and sensationalized media reporting. Study SnapshotPost TypeWeekly Literature Radar & Research IndexTotal Papers Indexed20 verified reportsPrimary RepositoriesPubMed, Europe PMC, ClinicalTrials.gov, OpenAlexCoverage WindowSeptember 13, 2026Lead FocusComparative Efficacy and Safety of Tirzepatide Versus Semagl Clinical Bottom Line The Weekly Literature Radar synthesizes 14 verified studies and updates into an actionable index, maintaining realistic clinical expectations and prioritizing patient safety. Emerging cannabinoid and metabolic research offers promising therapeutic insights, but individualized clinical guidance and monitored titration remain the gold standard of care. Patients should discuss new evidence with a qualified physician before modifying established treatment regimens. Weekly Literature Overview | 14 Studies & Reports Analyzed Welcome to the CED Clinic Weekly Literature Radar for September 13, 2026. This weekly index aggregates and translates 14 newly published biomedical studies, clinical trial protocols, open-access preprints, and health regulatory filings. By tracking multi-repository biomedical literature across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides patients, clinicians, and researchers with objective, evidence-grounded tracking of emerging science without overstating preliminary findings. Each indexed report is examined for study design, sample size, quantified outcomes, and direct clinical applicability. Translating primary data into clear clinical perspectives empowers healthcare providers and patients to make informed, collaborative decisions about medical cannabis and related therapies. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** News reports frequently frame findings like *“Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for “* as immediate therapeutic breakthroughs or universal treatment warnings without context. **Primary PubMed / Journal Evidence:** Analysis of published data in *PubMed* provides verified cohort measurements and specific outcome markers. Systematic trial evaluation demonstrates distinct endpoints that clarify dosage boundaries, response rates, and tolerability profiles. **Dr. Caplan’s Clinical Verdict:** Preliminary and single-center findings must be interpreted within their exact methodological boundaries. While providing valuable mechanistic and observational signals, they do not replace individualized clinical counseling, careful titration, or established safety protocols. Literature Card 1 | Comparative Efficacy and Safety of Tirzepatid **1. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.** *Source: PubMed (September 13, 2026) | PMID: 42732434 | DOI: 10.7759/cureus.114454*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42732434/) **Study Design & Cohort:** This systematic review followed PRISMA 2020 methods and searched PubMed/MEDLINE, Embase, Scopus, and Web of Science through 20 July 2026. It included 11 direct comparative studies, about 62,700 adults with overweight or obesity, consisting of one phase 3b open-label randomized active-controlled trial and 10 retrospective observational cohorts from multiple countries. Eligible studies directly compared subcutaneous tirzepatide with subcutaneous semaglutide and reported at least one anthropometric outcome. **Primary Findings:** Tirzepatide produced greater weight loss than semaglutide in every study that formally tested the comparison. In the randomized trial, mean weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide, and in real-world cohorts the adjusted between-group difference ranged from about 2.3 to 4.4 percentage points. Tirzepatide also showed greater improvements in blood pressure and HbA1c, with a lower incidence of new-onset type 2 diabetes, while gastrointestinal adverse events were the main side effects in both groups. **Clinical Relevance:** For patients seeking injectable obesity treatment, tirzepatide appears to deliver the larger average weight-loss response, especially when the goal is to reach higher thresholds such as 10% to 15% or more. In practice, I would expect the trial-level advantage to narrow somewhat in routine care, but the direction of benefit remains consistent, and the short-term tolerability profile is broadly similar to semaglutide. Choice still comes down to access, prior GLP-1 exposure, GI tolerance, glycemic goals, and careful review of concomitant diabetes therapies that may need dose adjustment as weight and glucose improve. Literature Card 2 | GLP-1 Receptor Agonists and Musculoskeletal O **2. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.** *Source: PubMed (September 13, 2026) | PMID: 42730869 | DOI: 10.1007/s40265-026-02365-3*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42730869/) **Study Design & Cohort:** This was a systematic review and meta-analysis conducted according to PRISMA, with searches of MEDLINE, CENTRAL, and Embase from inception through March 2025 plus manual bibliography review. The authors included 60 studies, 46 randomized controlled trials, 13 real-world evidence studies, and 1 pharmacovigilance study, representing 1,250,717 individuals exposed to GLP-1 receptor agonists or comparators. Agents studied included semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide, and other GLP-1 receptor agonists, with random-effects pooling for outcomes reported in at least 2 studies. **Primary Findings:** Using the most adjusted effect estimates, GLP-1 receptor agonists showed no significant effect on bone mineral density at any site or on fractures at any site. In the pooled muscle analysis, lean body mass or fat-free mass decreased significantly in the global model, with 28 contributing comparisons and a standardized mean difference of 0.52, 95% CI -0.8 to -0.23, I2 88%, p for heterogeneity --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).